SCHEMBL3220536

SCHEMBL3220536

CCOC(=O)CCNC(=O)CC(=O)OCC

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.56
MGAM O43451 1/20 0.56
SI P14410 1/20 0.56
MGAM2 Q2M2H8 1/20 0.56
CYP1A2 P05177 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
POLB P06746 2/20 0.43
MAPT P10636 1/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TRPA1 O75762 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
USP2 O75604 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244263 0.92 GAA (0.46) GAAMGAMSIMGAM2CYP1A2
SCHEMBL14902246 0.88 GAA (0.46) GAAMGAMSIMGAM2CYP1A2
SCHEMBL8565179 0.88 GAA (0.52) GAAMGAMSIMGAM2POLB
SCHEMBL5571264 0.88 KMT2A (0.52) GAAMGAMSIMGAM2CYP1A2
SCHEMBL5411533 0.86 GAA (0.48) GAAMGAMSIMGAM2CYP1A2
SCHEMBL5411539 0.86 GAA (0.48) GAAMGAMSIMGAM2CYP1A2
SCHEMBL15726347 0.86 CASP2 (0.52) GAAMGAMSIMGAM2CYP1A2
SCHEMBL4432951 0.86 GAA (0.48) GAAMGAMSIMGAM2CYP1A2
SCHEMBL5205850 0.86 GAA (0.45) GAAMGAMSIMGAM2CYP1A2
SCHEMBL3824078 0.84 GAA (0.46) GAAMGAMSIMGAM2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9827249-B2 Use of condensed benzo[B]thiazine derivatives as cytoprotectants ARANDA PHARMA LTD (FI) 2017-11-28 US disclosed
US-9777020-B2 Furo-3-carboxamide derivatives and methods of use ABBVIE INC. (US) 2017-10-03 US disclosed
EP-3097095-A1 FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE AbbVie Inc. (US) 2016-11-30 EP disclosed
US-20150210720-A1 FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE ABBVIE INC. 2015-07-30 US disclosed
WO-2015112754-A1 FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE ABBVIE INC. (US) 2015-07-30 WO disclosed
EP-2120933-B1 ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2015-07-08 EP disclosed
US-8293762-B2 Isoquinolinopyrrolopyridinones active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-10-23 US disclosed
US-20100113478-A1 INDOLONE MODULATORS OF 5-HT3 RECEPTOR AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-06 US disclosed
US-20100113478-A1 INDOLONE MODULATORS OF 5-HT3 RECEPTOR AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-06 US disclosed
US-20100113478-A1 INDOLONE MODULATORS OF 5-HT3 RECEPTOR AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-06 US disclosed
US-20100056556-A1 ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-03-04 US disclosed
EP-2120933-A1 ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2009-11-25 EP disclosed
WO-2008104475-A1 ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2008-09-04 WO disclosed
WO-2007068728-A2 N-SUBSTITUTED PYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2007-06-21 WO disclosed
US-20070142414-A1 N-substituted pyrrolopyridinones active as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2007-06-21 US disclosed
US-20020099070-A1 Dihydronaphthyridine potassium channel openers ABBOTT LABORATORIES 2002-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210720-A1 FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE NTRK2, MUSK, NTRK3 GAA 1610/4885MGAM 3311/4885SI 990/4885
US-20100113478-A1 INDOLONE MODULATORS OF 5-HT3 RECEPTOR HTR3A, HTR3B, HTR3E GAA 4689/4885MGAM 4700/4885SI 1402/4885
US-20100056556-A1 ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS CDK2, CDK1, CDK3 GAA 3492/4885MGAM 4316/4885SI 4251/4885
US-20070142414-A1 N-substituted pyrrolopyridinones active as kinase inhibitors CDK2, MAP3K19, MAP3K7 GAA 3382/4885MGAM 4194/4885SI 4260/4885
US-20020099070-A1 Dihydronaphthyridine potassium channel openers KCNH1, KCNN1, KCNJ2 GAA 1909/4885MGAM 4645/4885SI 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.